Clinical Trial Update: Safety, Efficacy, Tolerability and Pharmacokinetics of AGN-223575 Ophthalmic Suspension in Patients With Dry Eye Disease [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for AGN-223575 ophthalmic suspension in dry eye disease, reporting safety, efficacy, tolerability, and pharmacokinetics. Results c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Eye Disease

Drugs mentioned

• AGN-223575 ophthalmic suspension (AGN-223575)

Snippet

Sponsor: Allergan | Conditions: Dry Eye Syndromes | Phase 2 | Status: COMPLETED | Results posted: 2019-04-05